FR06C0049I2 - 3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques - Google Patents

3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques

Info

Publication number
FR06C0049I2
FR06C0049I2 FR06C0049C FR06C0049C FR06C0049I2 FR 06C0049 I2 FR06C0049 I2 FR 06C0049I2 FR 06C0049 C FR06C0049 C FR 06C0049C FR 06C0049 C FR06C0049 C FR 06C0049C FR 06C0049 I2 FR06C0049 I2 FR 06C0049I2
Authority
FR
France
Prior art keywords
triazoles
diphenyl
substituted
metal chelators
pharmaceutical metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0049C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR06C0049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR06C0049I1 publication Critical patent/FR06C0049I1/fr
Application granted granted Critical
Publication of FR06C0049I2 publication Critical patent/FR06C0049I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR06C0049C 1996-06-25 2006-12-26 3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques Active FR06C0049I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (2)

Publication Number Publication Date
FR06C0049I1 FR06C0049I1 (de) 2007-03-09
FR06C0049I2 true FR06C0049I2 (fr) 2007-04-27

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0049C Active FR06C0049I2 (fr) 1996-06-25 2006-12-26 3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques

Country Status (36)

Country Link
US (3) US6465504B1 (de)
EP (1) EP0914118B1 (de)
JP (1) JP3541042B2 (de)
KR (1) KR100616378B1 (de)
CN (1) CN1146415C (de)
AP (1) AP1127A (de)
AR (1) AR007479A1 (de)
AT (1) ATE226435T1 (de)
AU (1) AU718037B2 (de)
BG (1) BG64248B1 (de)
BR (1) BR9709973A (de)
CA (1) CA2255951C (de)
CY (2) CY2429B1 (de)
CZ (1) CZ291470B6 (de)
DE (3) DE122007000020I1 (de)
DK (1) DK0914118T3 (de)
ES (1) ES2187785T3 (de)
FR (1) FR06C0049I2 (de)
GE (1) GEP20084355B (de)
HU (1) HU226232B1 (de)
IL (1) IL127212A0 (de)
LT (1) LTC0914118I2 (de)
LU (1) LU91291I2 (de)
MY (1) MY129541A (de)
NL (1) NL300248I2 (de)
NO (3) NO317180B1 (de)
NZ (1) NZ333308A (de)
OA (1) OA10946A (de)
PL (1) PL194758B1 (de)
PT (1) PT914118E (de)
RU (1) RU2208010C2 (de)
SI (1) SI0914118T1 (de)
SK (1) SK284319B6 (de)
TR (1) TR199802693T2 (de)
TW (1) TW533205B (de)
WO (1) WO1997049395A1 (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
KR20060125810A (ko) * 2003-12-19 2006-12-06 노파르티스 아게 （ａ）엔-〔5-［4-（4-메틸-피페라지노-메틸）-벤조일아미도］-2메틸페닐〕-4-（3-피리딜）-2-피리미딘-아민 및（ｂ） 1종 이상의 하이퓨지네이션 억제제의 조합물 및그의 용도
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (de) * 2004-05-24 2009-06-10 Univ New York Verfahren zur behandlung oder prävention von pathologischen wirkungen einer akuten zunahme von hyperglykämie und/oder einer akuten zunahme von freiem fettsäurefluss
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
EP1853235A1 (de) * 2005-02-10 2007-11-14 Novartis AG Verfahren für verbesserte wirkstoffdisposition
MX2007015085A (es) * 2005-05-31 2008-01-17 Novartis Ag Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
US7947673B2 (en) 2005-11-01 2011-05-24 Novartis Ag Method of scintigraphy
ES2458615T3 (es) * 2006-02-03 2014-05-06 Taisho Pharmaceutical Co., Ltd. Derivado de triazol
US20090317489A1 (en) 2006-05-09 2009-12-24 Hanspeter Nick Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
EP2255805A1 (de) * 2006-05-23 2010-12-01 Novartis AG Deferasirox zur Behandlung ererbter Hämochromatose
TWI448285B (zh) 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
BRPI0715123A2 (pt) * 2006-08-04 2013-06-04 Novartis Ag tratamento de disfunÇço endàcrina usando quelantes de ferro
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP1927591A1 (de) * 2006-11-29 2008-06-04 Novartis AG Polymorphe Formen des Deferasirox (ICL670)
CA2670313C (en) * 2006-11-29 2013-02-12 Novartis Ag Polymorphic forms of deferasirox (icl670a)
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
JP2010526849A (ja) * 2007-05-14 2010-08-05 ノバルティス アーゲー 心筋梗塞の治療のための鉄キレート剤の使用
EP1994930A1 (de) * 2007-05-22 2008-11-26 Novartis AG Triazol-Verbindungen zur Behandlung der Biofilm Bildung
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (de) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmazeutische Zusammensetzungen
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
EP2291360A2 (de) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Feste formen von deferasiroxsalzen und verfahren zu deren herstellung
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
TWI488624B (zh) 2008-09-22 2015-06-21 Nat University Corp Asahikawa Medical College 鐵螯合劑、其製造方法及鐵離子之定量、捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
US20120093828A1 (en) 2009-03-19 2012-04-19 Ibrahim Ashraf S Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体
KR20130041144A (ko) 2010-07-08 2013-04-24 라티오팜 게엠베하 데페라시록스의 경구투여용 제제
WO2012025935A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
US9018389B2 (en) 2010-11-24 2015-04-28 Alembic Pharmaceuticals, Ltd. Process for the preparation of Deferasirox
EP2664333B1 (de) 2011-01-14 2016-10-12 Disease Adsorption System Technologies Co., Ltd. Polymere eisenchelatbildner
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
EP2766049A1 (de) 2011-10-14 2014-08-20 Photocure ASA Photodynamische diagnose von abweichungen des epithels der speiseröhre mit einem 5-ala ester
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
DK2964659T3 (da) * 2013-03-06 2017-11-27 Biocon Ltd Fremgangsmåde til fremstilling af deferasirox
SG11201506491RA (en) * 2013-03-08 2015-09-29 Novartis Ag Oral formulations of deferasirox
HK1215191A1 (zh) * 2013-05-10 2016-08-19 Cipla Limited 低剂量医药组合物
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
TR201909052T4 (tr) 2014-05-20 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroks içeren suda dağılabilen tablet formülasyonu.
EP2987482A1 (de) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Lösliche und dispergierbare pharmazeutische Formulierung enthaltend Deferasirox
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (de) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmazeutische zusammensetzung mit deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
EP4378957A3 (de) 2015-07-29 2024-08-07 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
KR101695970B1 (ko) 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
SG10202005377VA (en) 2015-10-23 2020-07-29 Vifor Int Ag Novel ferroportin inhibitors
EP3389712B1 (de) 2015-12-17 2024-04-10 Novartis AG Antikörpermoleküle gegen pd-1 und verwendungen davon
EP3429562A1 (de) 2016-03-17 2019-01-23 Lupin Limited Zusammensetzungen aus deferasirox
EP3507367A4 (de) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
EP3518904A1 (de) 2016-09-30 2019-08-07 Synthon B.V. Pharmazeutische zusammensetzung mit deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
EP4052698A1 (de) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Filmbeschichtete tablette mit deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
WO1997049395A1 (en) 1997-12-31
LU91291I9 (de) 2018-12-27
PT914118E (pt) 2003-02-28
FR06C0049I1 (de) 2007-03-09
CY2429B1 (en) 2004-11-12
EP0914118B1 (de) 2002-10-23
KR100616378B1 (ko) 2006-08-28
CN1223579A (zh) 1999-07-21
DE122007000020I2 (de) 2010-12-30
NL300248I2 (nl) 2007-03-01
DE122007000020I1 (de) 2007-05-24
DK0914118T3 (da) 2003-02-24
SI0914118T1 (en) 2003-04-30
NO2006017I1 (no) 2006-12-18
CN1146415C (zh) 2004-04-21
SK178598A3 (en) 1999-06-11
US20030203954A1 (en) 2003-10-30
AU718037B2 (en) 2000-04-06
IL127212A0 (en) 1999-09-22
AR007479A1 (es) 1999-10-27
PL330119A1 (en) 1999-04-26
PL194758B1 (pl) 2007-07-31
ES2187785T3 (es) 2003-06-16
BG64248B1 (bg) 2004-07-30
AP9801407A0 (en) 1998-12-31
JP2000507601A (ja) 2000-06-20
GEP20084355B (de) 2008-04-29
LTPA2007001I1 (lt) 2018-06-25
DE69716602T2 (de) 2003-06-26
US6465504B1 (en) 2002-10-15
NO317180B1 (no) 2004-09-06
CY2007005I2 (el) 2018-12-12
NZ333308A (en) 2000-05-26
TR199802693T2 (xx) 1999-05-21
AP1127A (en) 2002-12-06
NO2018014I2 (no) 2018-11-19
CA2255951C (en) 2006-10-10
CZ291470B6 (cs) 2003-03-12
MY129541A (en) 2007-04-30
SK284319B6 (sk) 2005-01-03
BG103003A (en) 1999-09-30
HK1020530A1 (en) 2000-05-12
RU2208010C2 (ru) 2003-07-10
HUP9903111A3 (en) 2000-06-28
NO986024D0 (no) 1998-12-21
US6723742B2 (en) 2004-04-20
NL300248I1 (nl) 2007-02-01
CA2255951A1 (en) 1997-12-31
AU3262997A (en) 1998-01-14
HUP9903111A2 (hu) 2000-01-28
ATE226435T1 (de) 2002-11-15
JP3541042B2 (ja) 2004-07-07
NO2018014I1 (no) 2018-04-17
NO986024L (no) 1998-12-21
CZ427298A3 (cs) 1999-03-17
LU91291I2 (fr) 2007-01-29
HU226232B1 (en) 2008-07-28
TW533205B (en) 2003-05-21
US6596750B2 (en) 2003-07-22
EP0914118A1 (de) 1999-05-12
CY2007005I1 (el) 2010-07-28
NO2006017I2 (no) 2011-07-04
OA10946A (en) 2003-02-27
KR20050098029A (ko) 2005-10-10
DE69716602D1 (de) 2002-11-28
US20030069273A1 (en) 2003-04-10
BR9709973A (pt) 1999-08-10
LTC0914118I2 (lt) 2018-12-27

Similar Documents

Publication Publication Date Title
IL127212A0 (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
EP0710667A3 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
PT915846E (pt) Fenilcetoenois 2-substituidos e 2,5-substituidos
TR199501560A2 (tr) Kademeli olarak saliverilen kafein formülasyonu.
PL329484A1 (en) Triazolyl merkaptides and their apllication as microbicides
BR9509805A (pt) Derivados de triazolila
ZA973503B (en) Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents.
ZA976222B (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
AU4009795A (en) Heterocyclic compounds and their use
AU3839895A (en) Heterocyclic compounds, their preparation and use
ZA9710979B (en) Novel heterocyclically substituted benzamides and their use
BR9500473A (pt) Composição sólida,composição de revestimento em pó e revestimento reticulado
EP1012266A4 (de) Galectin 8, 9, 10 und 10sv.
BR9500240A (pt) Amplificador de estado sólido
DE59607589D1 (de) N-aryl-1,2,4-triazolin-5-one
DE69534814D1 (de) Hängendes einzelrollendynamometer
DK0699427T3 (da) Sammenrullet menstruationsbeskyttelse
AU3650695A (en) New heterocyclic substituted imidazoloquinoxalinones, their preparation and their use
FR2722198B1 (fr) 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co
AU8617398A (en) Wound and injury treatment compositions and the use thereof
SI0888356T1 (en) Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
ZA972790B (en) Heterocyclic compounds and their preparation and use.
ES1035887Y (es) "dispositivo para la sujecion de tiques y similares".
KR950026632U (ko) 개량 롤식 휴지 케이스
BR1100852A (pt) Utilização dos compostos, e, composição farmacêutica